tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Steve Byrne, 27 are a SELL (16.36%), 89 are a BUY (53.94%), 49 are a HOLD (29.7%).
Analyst Steve Byrne, currently employed at BAML, carries an average stock price target met ratio of 61.56% that have a potential upside of 24.02% achieved within 231 days.
Steve Byrne’s has documented 604 price targets and ratings displayed on 34 stocks. The coverage is on Basic Materials, Consumer Defensive, Healthcare sectors.
Most recent stock forecast was given on SRPT, Sarepta Therapeutics at 23-Jul-2025.
Analyst best performing recommendations are on PCRX (PACIRA PHARMACEUTICALS).
The best stock recommendation documented was for GPRE (GREEN PLAINS RENEWABLE ENERGY) at 10/24/2022. The price target of $35 was fulfilled within 17 days with a profit of $7.74 (28.39%) receiving and performance score of 16.7.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$95
5 days ago
(30-Jul-2025)
22/35 (62.86%)
$34.7 (57.55%)
632
Hold
$60
$-7.85 (-11.57%)
$60
6 days ago
(29-Jul-2025)
19/25 (76%)
$-11.6 (-16.20%)
343
Hold
$75
$7.15 (10.54%)
$60
21 days ago
(14-Jul-2025)
15/21 (71.43%)
$3.13 (4.36%)
187
Hold
$57
$-10.85 (-15.99%)
$280
24 days ago
(11-Jul-2025)
6/7 (85.71%)
$-13.98 (-19.70%)
622
Sell
$58
$-9.85 (-14.52%)
$68
2 months 29 days ago
(06-May-2025)
10/10 (100%)
$0.51 (0.89%)
261
Which stock is Steve Byrne is most bullish on?
Which stock is Steve Byrne is most reserved on?
What Year was the first public recommendation made by Steve Byrne?
